

SUPPLEMENTAL MATERIAL

Table S1 Results of DOAC measurements, mean \pm SD and range (min-max)

	C-trough level N=1657		C-peak level N=1303	
	N (%)	ng/mL	N (%)	ng/mL
Apixaban	521 (31.4)	123 \pm 69 (8-468)	412 (31.6)	247 \pm 97 (16-784)
Dabigatran	221 (13.3)	106 \pm 64 (9-367)	190 (14.6)	217 \pm 102 (32-499)
Edoxaban	583 (35.3)	40 \pm 33 (7-284)	469 (36.0)	220 \pm 100 (6-497)
Rivaroxaban	332 (20.0)	37 \pm 30 (6-331)	232 (17.8)	215 \pm 99 (9-498)

DOAC: direct oral anticoagulants; SD = Standard Deviation

Table S2. Distribution of bleeding events (major and clinically relevant non-major bleeding) occurring during follow-up in all patients and in subgroups

Bleeding outcomes	No (N=1607)	Yes (N=50)	P
Major bleeding, n	---	30	
CRNMB, n	---	20	
Sex			
Female, n (%)	741 (46.1)	20 (40.0)	0.3941
Males, n (%)	866 (53.9)	30 (60.0)	
Age			
< 75, n (%)	529 (32.9)	11 (22.0)	0.1054
≥ 75, n (%)	1078 (67.1)	39 (78.0)	
DOAC dose			
Standard, n (%)	936 (58.2)	21 (42.0)	0.0224
Low, n (%)	671 (41.8)	29 (58.0)	
Weight			
≤ 60 Kg, n (%)	297 (18.5)	12 (24.0)	0.3258
> 60 Kg, n (%)	1310 (81.5)	38 (76.0)	
CHA ₂ DS ₂ VASc score			
< 4, n (%)	571 (35.5)	14 (28.0)	0.2745
≥ 4, n (%)	1036 (64.5)	36 (72.0)	
HAS-BLED,			
< 3, n (%)	643 (40.0)	18 (36.0)	0.5696
≥ 3, n (%)	964 (60.0)	32 (64.0)	
Creatinine clearance, mL/min			
≥ 60, n (%)	778 (48.4)	21 (42.0)	0.5606
30–59, n (%)	742 (46.2)	25 (50.0)	
< 30, n (%)	87 (5.4)	4 (8.0)	
Diabetes, %	355 (22.1)	12 (24.0)	0.7501
Hypertension, %	1385 (86.1)	46 (92.0)	0.2392
Previous stroke, transient ischemic attack, or embolism, %	180 (11.2)	3 (6.0)	0.2481
Antiplatelet use			
Aspirin, %	256 (15.9)	6 (12.0)	0.4565
Dual antiplatelet, %	20 (1.2)	0	0.4360
Nonsteroidal anti-inflammatory drug, %	45 (2.8)	2 (4.0)	0.6148
Bleeding history, %	47 (2.9)	3 (6.0)	0.2054
Liver disease, %	9 (0.6)	0	0.5958
Smoking history, %	182 (11.3)	8 (16.0)	0.3040

CRNMB: clinically relevant non-major bleeding

Table S3 Deaths (n=46)

	N (%)
Thrombotic complications	6 (13.0)
Bleeding complication	3 (6.5)
Cancer	9 (19.6)
Sepsis	5 (10.9)
SARS-CoV-2	5 (10.9)
Heart failure	5 (10.9)
Respiratory failure	3 (6.5)
Polytrauma	1 (2.2)
Acute renal insufficiency	1 (2.2)
Sudden death	1 (2.2)
Senile cachexia	2 (4.3)
Not specified but not OAT related	1 (2.2)
Unknown	4 (8.7)

AMI: acute myocardial infarction; OAT: oral anticoagulant therapy